ライフサイエンスコーパス: invasive pneumococcal disease

1 ca will have substantial indirect effects on invasive pneumococcal disease.

2 We assessed the effect of vaccination on invasive pneumococcal disease.

3 thesis genes promote growth and virulence in invasive pneumococcal disease.

4 Surveillance identified 35,192 cases of invasive pneumococcal disease.

5 at contributes to morbidity and mortality of invasive pneumococcal disease.

6 ferred protection against recolonization and invasive pneumococcal disease.

7 cedented success in controlling vaccine-type invasive pneumococcal disease.

8 and adults who had recovered from documented invasive pneumococcal disease.

9 ation with Streptococcus pneumoniae precedes invasive pneumococcal disease.

10 sease have a 600-fold increased incidence of invasive pneumococcal disease.

11 Adults infected with HIV have high rates of invasive pneumococcal disease.

12 such as malaria, HIV/AIDS, tuberculosis, and invasive pneumococcal disease.

13 ted subjects who had recently recovered from invasive pneumococcal disease.

14 o examine the association between asthma and invasive pneumococcal disease.

15 laboratory-based program of surveillance for invasive pneumococcal disease.

16 ates and demographic data from patients with invasive pneumococcal disease.

17 s, persons with AIDS remain at high risk for invasive pneumococcal disease.

18 n nine sites in seven European countries for invasive pneumococcal disease.

19 Asthma is an independent risk factor for invasive pneumococcal disease.

20 nst pneumococcal carriage, otitis media, and invasive pneumococcal disease.

21 could be at substantially increased risk of invasive pneumococcal disease.

22 these mutant genotypes were associated with invasive pneumococcal disease.

23 include those at highest risk for death from invasive pneumococcal disease.

24 all ages are disproportionately affected by invasive pneumococcal disease.

25 The primary endpoint was first event invasive pneumococcal disease.

26 coccus pneumoniae provide protection against invasive pneumococcal disease.

27 omen with (n = 21) or without (n = 33) prior invasive pneumococcal disease.

28 ic in these patients who are at high risk of invasive pneumococcal disease.

29 de and timing of indirect effects of PCVs on invasive pneumococcal disease.

30 y activity, thus affecting the resistance to invasive pneumococcal disease.

31 not rescue cigarette smoke-exposed mice from invasive pneumococcal disease.

32 s far unrecognized role in the resistance to invasive pneumococcal disease.

33 e PCV13 can expect substantial reductions in invasive pneumococcal disease.

34 patients, in whom we identified 320 cases of invasive pneumococcal disease.

35 to identify community-acquired pneumonia and invasive pneumococcal disease.

36 ed in hearts of mice that had recovered from invasive pneumococcal disease.

37 eumococcal community-acquired pneumonia, and invasive pneumococcal disease.

38 ealth England funds national surveillance of invasive pneumococcal disease.

39 e (SCD) have significantly increased risk of invasive pneumococcal disease.

40 l, active, laboratory-based surveillance for invasive pneumococcal disease.

41 hat contribute to cardiac dysfunction during invasive pneumococcal disease: (1) cell wall-mediated in

42 For each subject with invasive pneumococcal disease, 10 age-matched controls w

43 seline, there was a 56% overall reduction in invasive pneumococcal disease (15.63 vs 6.85 per 100,000

44 94.8) and against antibiotic non-susceptible invasive pneumococcal disease (65.6%, 44.9 to 78.7).

45 Persons with asthma had an increased risk of invasive pneumococcal disease (adjusted odds ratio, 2.4;

46 uded vaccine effectiveness against all-cause invasive pneumococcal disease, against antibiotic non-su

47 in recent decreases in the rate of PCV7-type invasive pneumococcal disease among adults.

48 Serotype 19A accounted for 28.3% of invasive pneumococcal disease among Alaska children youn

49 se is associated with the overall decline in invasive pneumococcal disease among Alaska Native childr

50 Despite higher rates of invasive pneumococcal disease among blacks and persons w

51 Rates of invasive pneumococcal disease among children in South Af

52 PCV13 appears highly effective against invasive pneumococcal disease among children in the USA

53 Ratio of the number of cases of invasive pneumococcal disease among HIV-infected adults

54 e was associated with an overall decrease in invasive pneumococcal disease among HIV-infected adults,

55 is the strongest independent risk factor for invasive pneumococcal disease among immunocompetent, non

56 The risk of invasive pneumococcal disease among persons with asthma

57 ed in a two-stage study of 337 patients with invasive pneumococcal disease and 1032 controls.

58 We enrolled 722 children with invasive pneumococcal disease and 2991 controls; PCV13 s

59 A total of 635 persons with invasive pneumococcal disease and 6350 controls were ide

60 52% (95% CI -12 to 79) against all-serotype invasive pneumococcal disease and 94% (44 to 100) for se

61 been associated with decreases in PCV7-type invasive pneumococcal disease and nasopharyngeal (NP) ca

62 r than age 2 years have the highest rates of invasive pneumococcal disease and play an important role

63 atients with proven (blood culture-positive) invasive pneumococcal disease and pneumonia of unknown e

64 nization of mice with GlpO protected against invasive pneumococcal disease and provided additive prot

65 We recorded episodes of invasive pneumococcal disease and serotyped isolates.

66 antibodies to PotD confer protection against invasive pneumococcal disease and that this protein shou

67 disease, against antibiotic non-susceptible invasive pneumococcal disease, and among children with a

68 ncy virus (HIV) infection increases rates of invasive pneumococcal disease, and its effect on coloniz

69 mately half of otherwise healthy adults with invasive pneumococcal disease are cigarette smokers.

70 ents who were 18 to 64 years old and who had invasive pneumococcal disease (as defined by the isolati

71 , Vietnam and several African countries with invasive pneumococcal disease, bacteremia, malaria and t

72 We compared the incidence of invasive pneumococcal disease between baseline (May 12,

73 tios (IRRs) for vaccine and non-vaccine type invasive pneumococcal disease between July, 2013, and Ju

74 evant to the continued efforts to reduce the invasive pneumococcal disease burden.

75 ommunity-acquired pneumonia and vaccine-type invasive pneumococcal disease but not in preventing comm

76 Patients with AIDS have a high incidence of invasive pneumococcal disease, but no population-based d

77 Older adults are at high risk of developing invasive pneumococcal disease, but the optimal timing an

78 d Wales has reduced the overall incidence of invasive pneumococcal disease by more than 50%.

79 propose that cigarette smoke predisposes to invasive pneumococcal disease by suppressing inflammator

80 i) different assumptions about the number of invasive pneumococcal disease cases adjusted for the inc

81 set of electronically reported and serotyped invasive pneumococcal disease cases in England and Wales

82 Invasive pneumococcal disease cases were identified by l

83 INTERPRETATION: The incidence of invasive pneumococcal disease caused by all serotypes de

84 By contrast, that of invasive pneumococcal disease caused by non-PCV13 seroty

85 The pooled IRR for invasive pneumococcal disease caused by non-PCV13 seroty

86 ency virus (HIV), the estimated incidence of invasive pneumococcal disease caused by PCV7 serotypes d

87 Worldwide, invasive pneumococcal disease caused by Streptococcus pn

88 ave millions of lives annually by preventing invasive pneumococcal disease caused by Streptococcus pn

89 ever, we noted no changes in either group in invasive pneumococcal disease caused by the additional 1

90 mate temporal indirect effects by pooling of invasive pneumococcal disease changes by serotype and se

91 erimental or observational studies reporting invasive pneumococcal disease changes following PCV intr

92 t the potential differences in prevention of invasive pneumococcal disease compared with nonbacteremi

93 Invasive pneumococcal disease continues to be a major ca

94 Invasive pneumococcal disease declined among children an

95 The annual incidence of invasive pneumococcal disease declined from 1094 cases/1

96 for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% f

97 lent pneumococcal conjugate vaccine, overall invasive pneumococcal disease decreased 67% in Alaska Na

98 ction of the PCV programme, the incidence of invasive pneumococcal disease decreased by 55% (95% CI 3

99 In the 2-4 years age group, the incidence of invasive pneumococcal disease decreased by 56% (95% CI 2

100 en 1998 and 2002, annual incidence rates for invasive pneumococcal disease decreased from 19.0 to 12.

101 Invasive pneumococcal disease, defined as isolation of S

102 (3%) died overall and 29 (8%) patients with invasive pneumococcal disease died.

103 e children have some of the highest rates of invasive pneumococcal disease documented in the world.

104 There is, however, evidence of increasing invasive pneumococcal disease due to non-PCV13 serotypes

105 Active surveillance identified cases of invasive pneumococcal disease during 1996-1997.

106 The demonstration of replacement invasive pneumococcal disease emphasizes the importance

107 The seasonal patterns of invasive pneumococcal disease epidemics varied significa

108 PnCRM7 vaccine prevents vaccine serotype invasive pneumococcal disease even in a high risk popula

109 We calculated cumulative incidence rates for invasive pneumococcal disease for 1994-2002 using popula

110 ounger than 5 years with suspected or proven invasive pneumococcal disease from 18 hospitals or insti

111 olates obtained from pediatric patients with invasive pneumococcal disease from 1994 to 2014 and 48 i

112 Among 76 patients with invasive pneumococcal disease from whom blood culture is

113 r children in October 2000, the incidence of invasive pneumococcal disease has declined dramatically,

114 Although invasive pneumococcal disease has declined substantially

115 ervational study of adults hospitalized with invasive pneumococcal disease in 2 Spanish hospitals was

116 Of 8582 cases of invasive pneumococcal disease in adults, 2013 (24%) occu

117 The incidence of invasive pneumococcal disease in Atlanta fell from 30.2

118 We assessed PCV10 effectiveness against invasive pneumococcal disease in Brazilian children.

119 mbian PCV programme reduced the incidence of invasive pneumococcal disease in children aged 2-59 mont

120 Cases of invasive pneumococcal disease in children aged 5 years o

121 Articles addressed the epidemiology of invasive pneumococcal disease in children in other count

122 veness of two or more doses of PCV13 against invasive pneumococcal disease in children with HIV infec

123 ducing high-valency PCVs on the incidence of invasive pneumococcal disease in children younger than 5

124 e pooled IRR was 0.53 (95% CI 0.43-0.65) for invasive pneumococcal disease in children younger than 5

125 and recommended in the USA for prevention of invasive pneumococcal disease in children.

126 We compared the incidence of invasive pneumococcal disease in each of the 4 years aft

127 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 yea

128 nterview Survey (NHIS) to determine rates of invasive pneumococcal disease in healthy adults (> or =1

129 seline (1998 to 1999) and 2003, the ratio of invasive pneumococcal disease in HIV-infected adults to

130 redisease alpha-PLY titer is associated with invasive pneumococcal disease in HIV-seropositive inject

131 eased TLR2 signaling with increased rates of invasive pneumococcal disease in humans.

132 conducted population-based surveillance for invasive pneumococcal disease in individuals aged 2 mont

133 After licensure of a conjugate vaccine for invasive pneumococcal disease in infants, new conjugate

134 from active population-based surveillance of invasive pneumococcal disease in metropolitan Atlanta we

135 was a report of the decreased occurrence of invasive pneumococcal disease in patients being provided

136 We examined data on invasive pneumococcal disease in patients identified fro

137 atins may be of prophylactic benefit against invasive pneumococcal disease in patients with SCD and,

138 The risks of invasive pneumococcal disease in persons with specific c

139 to conduct population-based surveillance for invasive pneumococcal disease in select regions of the A

140 Serotype 1 is an important cause of invasive pneumococcal disease in South Africa and has de

141 Incidence of invasive pneumococcal disease in the epidemiological yea

142 We measured the effect of these vaccines on invasive pneumococcal disease in The Gambia where the 7-

143 the experience at children's hospitals with invasive pneumococcal disease in the years pre- and post

144 In a model of invasive pneumococcal disease in TLR4-defective mice, th

145 ly reduced the incidence of vaccine-serotype invasive pneumococcal disease in young children and in u

146 Our goal was to describe trends in invasive pneumococcal disease incidence among persons wi

147 In the United States, invasive pneumococcal disease incidence declined sharply

148 3, the model suggests a reduction in overall invasive pneumococcal disease incidence in all cases.

149 During the final year of the study, the invasive pneumococcal disease incidence in persons with

150 We used time-trend analysis of annual invasive pneumococcal disease incidence rates from a pop

151 ugate vaccine use would cause an increase in invasive pneumococcal disease incidence, while replacing

152 Invasive pneumococcal disease incidences decreased betwe

153 For the 706 cases of invasive pneumococcal disease included in the study, PCV

154 Admissions for invasive pneumococcal disease increased from the 1990s r

155 Although blacks remain at higher risk of invasive pneumococcal disease, introduction of childhood

156 monitor post-PCV changes in the incidence of invasive pneumococcal disease (IPD) among children under

157 e impact of the 7-valent PCV on all-serotype invasive pneumococcal disease (IPD) among children was r

158 we assessed the serotype-specific burden of invasive pneumococcal disease (IPD) among immunocompromi

159 haracteristics, and serotype distribution of invasive pneumococcal disease (IPD) among Navajo childre

160 Certain chronic diseases increase risk for invasive pneumococcal disease (IPD) and are indications

161 e USA and resulted in dramatic reductions in invasive pneumococcal disease (IPD) and moderate increas

162 r roles during early stages of infection and invasive pneumococcal disease (IPD) are less well define

163 coccal serotype dynamics among children with invasive pneumococcal disease (IPD) as predicted by the

164 onjugate vaccine (PCV) in protecting against invasive pneumococcal disease (IPD) calls for alternate

165 (pneumococcus) caused approximately 44000 US invasive pneumococcal disease (IPD) cases in 2008.

166 We estimated the rate of increase of invasive pneumococcal disease (IPD) caused by serotype 1

167 ugate vaccine to the United States, rates of invasive pneumococcal disease (IPD) caused by serotype 6

168 We evaluated trends in invasive pneumococcal disease (IPD) caused by serotypes

169 Outbreaks of invasive pneumococcal disease (IPD) caused by Streptococ

170 ectively) are highly effective in preventing invasive pneumococcal disease (IPD) caused by vaccine se

171 Antibiotic-nonsusceptible invasive pneumococcal disease (IPD) decreased substantia

172 About 10% of pediatric patients with invasive pneumococcal disease (IPD) die from the disease

173 We used national surveillance of invasive pneumococcal disease (IPD) from 2002 for baseli

174 We obtained ZIP code-level data on invasive pneumococcal disease (IPD) from an active popul

175 e, but direct comparisons of impacts against invasive pneumococcal disease (IPD) in equivalent popula

176 We aimed to describe the epidemiology of invasive pneumococcal disease (IPD) in HEU infants.

177 the effectiveness of >/=2 PCV7 doses against invasive pneumococcal disease (IPD) in human immunodefic

178 ally thought to confer an increased risk for invasive pneumococcal disease (IPD) in humans.

179 ent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal disease (IPD) in infants aged <90

180 tion, outcome, and quality of life lost from invasive pneumococcal disease (IPD) in the context of th

181 e serotype 1 is one of the leading causes of invasive pneumococcal disease (IPD) in West Africa, with

182 Changes in invasive pneumococcal disease (IPD) incidence were evalu

183 mber 2006 has markedly reduced the burden of invasive pneumococcal disease (IPD) including meningitis

184 Serotype 19A invasive pneumococcal disease (IPD) increased annually i

185 Invasive pneumococcal disease (IPD) is 3-5 times more co

186 Invasive pneumococcal disease (IPD) is a leading cause o

187 irulence proteins in pediatric patients with invasive pneumococcal disease (IPD) is a valuable approa

188 Invasive pneumococcal disease (IPD) is an important caus

189 Invasive pneumococcal disease (IPD) is usually caused by

190 ococcal conjugate (PCV7) vaccine's impact on invasive pneumococcal disease (IPD) is well described, b

191 ng 594 Streptococcus pneumoniae serotype 19A invasive pneumococcal disease (IPD) isolates collected f

192 alent pneumococcal conjugate vaccine (PCV7), invasive pneumococcal disease (IPD) rates among blacks w

193 Vaccine-serotype (VT) invasive pneumococcal disease (IPD) rates declined subst

194 Winnipeg, Canada, experienced a doubling of invasive pneumococcal disease (IPD) rates, with a signif

195 rmines the propensity of an isolate to cause invasive pneumococcal disease (IPD) remains unknown.

196 to assess the value of molecular assays for invasive pneumococcal disease (IPD) surveillance in Sout

197 y syndrome (AIDS) have a higher incidence of invasive pneumococcal disease (IPD) than other adults, a

198 vice to all children within the program with invasive pneumococcal disease (IPD) to confirm an adequa

199 ect of these programs on the epidemiology of invasive pneumococcal disease (IPD) to determine if PCV-

200 ut pneumococcal population genomics in adult invasive pneumococcal disease (IPD) under vaccine pressu

201 tibody titers and resistance of mice against invasive pneumococcal disease (IPD) was determined.

202 The dynamics of invasive pneumococcal disease (IPD) were determined usin

203 es (PCVs) are highly effective in preventing invasive pneumococcal disease (IPD), but deaths due to I

204 This study aimed to estimate, following invasive pneumococcal disease (IPD), the proportion of c

205 considerably to the burden of pneumonia and invasive pneumococcal disease (IPD), with the effectiven

206 We explored PCV13's effect in reducing invasive pneumococcal disease (IPD)-related morbidity an

207 nfluence the propensity of a strain to cause invasive pneumococcal disease (IPD).

208 reptococcus pneumoniae, but very few develop invasive pneumococcal disease (IPD).

209 ed antibiotic resistance in isolates causing invasive pneumococcal disease (IPD).

210 Ra) is required for adequate host defense in invasive pneumococcal disease (IPD).

211 umococcal serotypes are most likely to cause invasive pneumococcal disease (IPD).

212 cterized the role of sex on the incidence of invasive pneumococcal disease (IPD).

213 nfected individuals are at increased risk of invasive pneumococcal disease (IPD).

214 CVs) affect rates of adult serotype-specific invasive pneumococcal disease (IPD).

215 vaccination in children aged 5-15 years with invasive pneumococcal disease (IPD).

216 14, 18C, 19F, and 23F, dramatically reduced invasive pneumococcal disease (IPD); however, the effect

217 ia, nonbacteremic pneumonia and nonpneumonia invasive pneumococcal diseases (IPD) in the pre-PCV era.

218 Invasive pneumococcal diseases (IPDs) remain the leading

219 e sought to determine whether seasonality of invasive pneumococcal disease is caused by increased nas

220 njugate vaccines in infants, among whom most invasive pneumococcal disease is vaccine-preventable.

221 e (PCV7) in 2000 reduced macrolide-resistant invasive pneumococcal disease (MR-IPD) due to PCV7 serot

222 th (July 1-June 30) for all-cause pneumonia, invasive pneumococcal disease, non-invasive pneumococcal

223 fficacy, 45.0%; 95.2% CI, 14.2 to 65.3), and invasive pneumococcal disease occurred in 7 persons in t

224 Patients were 15,923 persons with invasive pneumococcal disease occurring between January

225 among younger adults (eg, the proportion of invasive pneumococcal disease occurring in adults < 65 y

226 Invasive pneumococcal disease occurs 2-3-fold more often

227 overed by PCV13 in a cohort of patients with invasive pneumococcal disease of respiratory origin and

228 Since 2004, the invasive pneumococcal disease rate caused by nonvaccine

229 During invasive pneumococcal disease, S. pneumoniae can gain ac

230 igarette smoking is a strong risk factor for invasive pneumococcal disease, the underlying mechanisms

231 We assessed vaccine effectiveness against invasive pneumococcal disease using the indirect cohort

232 Among at-risk children, rate ratios for invasive pneumococcal disease (vs children without at-ri

233 existing conditions, the annual incidence of invasive pneumococcal disease was 4.2 episodes per 10,00

234 Vaccine effectiveness against all-cause invasive pneumococcal disease was 60.2% (95% CI 46.8 to

235 r more doses of PCV13 against PCV13-serotype invasive pneumococcal disease was 85% (95% CI 37 to 96)

236 Vaccine effectiveness against PCV7-serotype invasive pneumococcal disease was 87% (95% CI 38 to 97)

237 Invasive pneumococcal disease was associated with cigare

238 Population-based prospective surveillance of invasive pneumococcal disease was done in Southern Calif

239 d mean times to attaining a 90% reduction in invasive pneumococcal disease were 8.9 years (95% credib

240 study period, 173 of 1207 episodes (14%) of invasive pneumococcal disease were identified as PM; 76

241 atric patients in Bamako, Mali, 106 cases of invasive pneumococcal disease were identified from June

242 cal disease, 10 age-matched controls without invasive pneumococcal disease were randomly selected fro

243 data from population-based surveillance for invasive pneumococcal disease with data from the 1990 US

244 Native children are experiencing replacement invasive pneumococcal disease with serotypes not covered